Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up News

Executive Summary

Noteworthy news from medtech start-ups. This month we profile NinePoint Medical, which is developing technology for real-time diagnosis of esophogeal cancer and e(ye)BRAIN, which aims to diagnose neurological disorders by tracking eye movements. These company profiles first appeared in Start-Up magazine.

You may also be interested in...



Top Device Stories of 2010: A Look Back and a Glance Forward

This article was adapted from "Top Device Stories of 2010: Waiting for the Other Shoes to Fall," in the January 2011 issue of IN VIVO.

Shionogi's Oral COVID Drug Set For Global Access Through MPP

Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel